IPP Bureau
Sanofi India appoints Rahul Bhatnagar as Chairman of Board of Directors
By IPP Bureau - May 03, 2026
Rahul Bhatnagar succeeds Aditya Narayan, who completed a decade-long distinguished tenure
FDA grants breakthrough status to Laguna's mRNA blood test for schizophrenia diagnosis
By IPP Bureau - May 02, 2026
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
FDA renews IQOS “reduced-risk” status backing PMI’s smoke-free strategy in regulatory win
By IPP Bureau - May 02, 2026
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Bayer pushes stroke prevention drug forward in China as regulators accept key filing
By IPP Bureau - May 02, 2026
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
IMCD posts steady Q1 2026 performance with €130 million EBITA amid global uncertainty
By IPP Bureau - May 02, 2026
The company posted revenue of €1,267 million, up 6% on a constant currency basis
Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate
By IPP Bureau - May 02, 2026
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
Thermo Fisher opens flagship US Bioprocess Design Center in Massachusetts
By IPP Bureau - May 02, 2026
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
Thermo Fisher to sell microbiology business in $1.075 billion deal with Astorg
By IPP Bureau - May 02, 2026
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
By IPP Bureau - May 02, 2026
But acquisition charges drag earnings into loss
Indoco Remedies to exit ophthalmic business in strategic sale to Sunways India
By IPP Bureau - May 02, 2026
The transaction marks a clear portfolio reshuffle for Indoco
Dr Lal PathLabs posts strong Q4 FY26 results with 16.6% revenue growth & PAT at Rs. 132 Cr
By IPP Bureau - May 02, 2026
The company posted revenue of Rs. 703 crore in Q4 FY26
Aster DM Healthcare surges in Q4
By IPP Bureau - May 02, 2026
Merger momentum builds as profits jump
Pawan Varshney elevated to Director of Finance – South Asia at Cepheid
By IPP Bureau - May 01, 2026
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Nitin Wadhwa joins Sebia as General Manager to lead India growth
By IPP Bureau - May 01, 2026
Wadhwa brings over two decades of experience driving growth, transformation, and customer-centric strategies in the medical devices and diagnostics sector
PFCD panel flags insurance gaps limiting access to robotic joint replacement in India
By IPP Bureau - May 01, 2026
Leading orthopaedic experts call for equitable insurance coverage to patients for accessing advanced, precision-driven joint replacement technologies
